Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/920465/000092046518000048/ljpc-2018q3document.htm
August 2022
July 2022
February 2022
November 2021
July 2021
January 2021
December 2020
November 2020
October 2020
October 2020
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/920465/000092046518000048/ljpc-2018q3document.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by La Jolla Pharmaceutical Co.
La Jolla Pharmaceutical Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
Rating
Learn More![]()
The increase in cash provided by financing activities for the nine months ended September 30, 2018 was primarily the result of $109.8 million of net proceeds from the March 2018 common stock offering and $124.3 million of net proceeds from the May 2018 royalty financing.
In patients with a baseline MAP < 65 mmHg, a trend towards improved 28-day mortality was seen in the GIAPREZA group compared to the placebo group: 28-day mortality was 54.2% n = 52 for the GIAPREZA group compared to 70.4% n = 50 for the placebo group hazard ratio=0.66 95% CI: 0.40, 1.09 p=0.10.
toward longer survival over the 28-day study period: 22% reduction in mortality risk through day 28 hazard ratio=0.78 0.57-1.07, p=0.12 for GIAPREZA-treated patients.
The pre-specified analysis showed that a relatively low angiotensin II state as measured by the ratio of angiotensin I to angiotensin II predicted increased mortality in patients with vasodilatory shock, suggesting that a low angiotensin II state is a negative prognostic indicator of outcomes.
The inability to achieve or maintain adequate blood pressure results in inadequate blood flow to the bodys organs and tissue and is associated with a mortality rate exceeding most acute conditions requiring hospitalization.
Our highest priorities remain the...Read more
The Companys highest priorities remain...Read more
There have been no material...Read more
Furthermore, the analysis showed a...Read more
During the three and nine...Read more
The GIAPREZA clinical development program...Read more
The increase was primarily due...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
La Jolla Pharmaceutical Co provided additional information to their SEC Filing as exhibits
Ticker: LJPC
CIK: 920465
Form Type: 10-Q Quarterly Report
Accession Number: 0000920465-18-000048
Submitted to the SEC: Wed Oct 24 2018 4:01:27 PM EST
Accepted by the SEC: Wed Oct 24 2018
Period: Sunday, September 30, 2018
Industry: Biological Products No Disgnostic Substances